<DOC>
	<DOC>NCT01484990</DOC>
	<brief_summary>A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects with Advanced Parkinson's Disease.</brief_summary>
	<brief_title>A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects With Advanced Parkinson's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa, levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Inclusion Criteria 1. Male or female subjects at least 30 years old; 2. Subjects with advanced Parkinson's disease who are already on LCIG (DuodopaÂ®) for at least 30 days; 3. Body mass index range from 18.0 to 30.0 kg/m2 Exclusion Criteria 1. Subjects who are considered to be violent or subjects considered at suicidal risk by the investigator; 2. Clinically significant abnormal laboratory data at baseline or any abnormal laboratory value that could interfere with the study assessments; 3. Subjects with serious symptomatic cerebral disease, cerebrovascular disease, focal neurological lesions (previous brain surgery), any acute brain trauma requiring treatment with anticonvulsant therapy, or acute stroke</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Parkinson's Disease</keyword>
	<keyword>levodopa</keyword>
	<keyword>carbidopa</keyword>
	<keyword>Duodopa</keyword>
	<keyword>intestinal gel</keyword>
</DOC>